These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 9698079

  • 1. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
    Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP, Shimada T.
    Biochem Pharmacol; 1998 Jul 15; 56(2):243-51. PubMed ID: 9698079
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, Nomizo Y, Muramoto N, Kimura S, Echizen H.
    Pharmacogenetics; 1998 Oct 15; 8(5):365-73. PubMed ID: 9825828
    [Abstract] [Full Text] [Related]

  • 4. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T.
    Pharmacogenetics; 1997 Apr 15; 7(2):103-13. PubMed ID: 9170147
    [Abstract] [Full Text] [Related]

  • 5. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
    Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA.
    Pharmacogenetics; 1996 Aug 15; 6(4):341-9. PubMed ID: 8873220
    [Abstract] [Full Text] [Related]

  • 6. Allelic and functional variability of cytochrome P4502C9.
    Bhasker CR, Miners JO, Coulter S, Birkett DJ.
    Pharmacogenetics; 1997 Feb 15; 7(1):51-8. PubMed ID: 9110362
    [Abstract] [Full Text] [Related]

  • 7. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates.
    Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K.
    Pharmacogenetics; 2000 Mar 15; 10(2):95-104. PubMed ID: 10761997
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
    Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ.
    Drug Metab Dispos; 2002 Apr 15; 30(4):385-90. PubMed ID: 11901091
    [Abstract] [Full Text] [Related]

  • 15. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N.
    Epilepsia; 1998 Dec 15; 39(12):1317-23. PubMed ID: 9860067
    [Abstract] [Full Text] [Related]

  • 16. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, Inui K.
    Clin Pharmacol Ther; 1997 Sep 15; 62(3):287-92. PubMed ID: 9333104
    [Abstract] [Full Text] [Related]

  • 17. Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen.
    Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, Korzekwa KR.
    Biochem Pharmacol; 1995 May 11; 49(9):1269-75. PubMed ID: 7763308
    [Abstract] [Full Text] [Related]

  • 18. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H, Echizen H.
    Clin Pharmacokinet; 2001 May 11; 40(8):587-603. PubMed ID: 11523725
    [Abstract] [Full Text] [Related]

  • 19. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.
    Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S.
    Ther Drug Monit; 1998 Jun 11; 20(3):243-7. PubMed ID: 9631918
    [Abstract] [Full Text] [Related]

  • 20. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.
    Hanatani T, Fukuda T, Ikeda M, Imaoka S, Hiroi T, Funae Y, Azuma J.
    Pharmacogenomics J; 2001 Jun 11; 1(4):288-92. PubMed ID: 11908770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.